Suppression of NLRP3 Inflammasome Activation Ameliorates Chronic Kidney Disease-Induced Cardiac Fibrosis and Diastolic Dysfunction

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Bugyei Twum, Antoinette ^a,b   Abadeh, Armin ^a   Thai, Kerri ^a   Zhang, Yanling ^a   Mitchell, Melissa ^a   Kabir, Golam ^a   Connelly, Kim A ^a,b,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1BETA; NLRP3 PROTEIN, RAT; POLYPHENOL;

ANIMAL; BLOOD PRESSURE; BODY WEIGHT; CARDIAC MUSCLE; CHEMISTRY; CHRONIC KIDNEY FAILURE; COMPLICATION; CYTOLOGY; DIASTOLE; ECHOCARDIOGRAPHY; FIBROSIS; MACROPHAGE; MALE; METABOLISM; NEPHRECTOMY; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD PRESSURE; BODY WEIGHT; DIASTOLE; ECHOCARDIOGRAPHY; FIBROSIS; INFLAMMASOMES; INTERLEUKIN-1BETA; KIDNEY FAILURE, CHRONIC; MACROPHAGES; MALE; MYOCARDIUM; NEPHRECTOMY; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; POLYPHENOLS; RATS; RATS, SPRAGUE-DAWLEY; RENAL INSUFFICIENCY, CHRONIC;

EID: 85007021133     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep39551     Document Type: Article

References (40)

1. Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351, 1296-1305 (2004).
2. Schrier, R. W. Cardiorenal versus renocardiac syndrome: is there a difference? Nat Clin Pract Nephrol 3, 637 (2007).
3. Tyralla, K. & Amann, K. Cardiovascular changes in renal failure. Blood Purif 20, 462-465 (2002).
4. Tyralla, K. & Amann, K. Morphology of the heart and arteries in renal failure. Kidney Int Suppl, S80-83 (2003).
5. Leemans, J. C., Cassel, S. L. & Sutterwala, F. S. Sensing damage by the NLRP3 inflammasome. Immunol Rev 243, 152-162 (2011).
6. Melnikov, V. Y. et al. Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J Clin Invest 107, 1145-1152 (2001).
7. Melnikov, V. Y. et al. Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J Clin Invest 110, 1083-1091 (2002).
8. Parikh, C. R., Abraham, E., Ancukiewicz, M. & Edelstein, C. L. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol 16, 3046-3052 (2005).
9. Vilaysane, A. et al. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol 21, 1732-1744 (2010).
10. Garg, N. J. Inflammasomes in cardiovascular diseases. Am J Cardiovasc Dis 1, 244-254 (2011).
11. Anand, P., Kunnumakkara, A. B., Newman, R. A. & Aggarwal, B. B. Bioavailability of curcumin: problems and promises. Mol Pharm 4, 807-818 (2007).
12. Sasaki, H. et al. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull 34, 660-665 (2011).
13. Ghosh, S. S. et al. Curcumin ameliorates renal failure in 5/6 nephrectomized rats: role of inflammation. Am J Physiol Renal Physiol 296, F1146-1157 (2009).
14. Ghosh, S. S. et al. Curcumin prevents cardiac remodeling secondary to chronic renal failure through deactivation of hypertrophic signaling in rats. Am J Physiol Heart Circ Physiol 299, H975-984 (2010).
15. Hernandez-Resendiz, S. et al. Cardioprotection by curcumin post-treatment in rats with established chronic kidney disease. Cardiovasc Drugs Ther 29, 111-120 (2015).
16. Fujihara, C. K., Velho, M., Malheiros, D. M. & Zatz, R. An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int 67, 1913-1924 (2005).
17. Fujihara, C. K., Malheiros, D. M. & Zatz, R. Losartan-hydrochlorothiazide association promotes lasting blood pressure normalization and completely arrests long-term renal injury in the 5/6 ablation model. Am J Physiol Renal Physiol 292, F1810-1818 (2007).
18. Teles, F. et al. Regression of glomerular injury by losartan in experimental diabetic nephropathy. Kidney Int 75, 72-79 (2009).
19. Parving, H. H., Andersen, A. R., Hommel, E. & Smidt, U. Effects of long-term antihypertensive treatment on kidney function in diabetic nephropathy. Hypertension 7, II114-117 (1985).
20. Asselbergs, F. W. et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110, 2809-2816 (2004).
21. de Zeeuw, D. et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110, 921-927 (2004).
22. Selvarajah, S. et al. Renal impairment and all-cause mortality in cardiovascular disease: effect modification by type 2 diabetes mellitus. Eur J Clin Invest 43, 198-207 (2013).
23. Lopez, B., Gonzalez, A., Hermida, N., Laviades, C. & Diez, J. Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. Kidney Int Suppl, S19-23 (2008).
24. Amann, K. & Tyralla, K. Cardiovascular changes in chronic renal failure-pathogenesis and therapy. Clin Nephrol 58 Suppl 1, S62-72 (2002).
25. Morimoto, T., W. H., Sunagawa, Y. et al. Highly absorptive curcumin improves left ventricula diastolic function regardless of blood pressure in hypertensive patients. J Am Coll Cardiol. 59(13s1):E987 (2012).
26. Stenvinkel, P. Inflammation in end-stage renal disease: the hidden enemy. Nephrology (Carlton) 11, 36-41 (2006).
27. Kuwabara, N. et al. Attenuation of renal fibrosis by curcumin in rat obstructive nephropathy. Urology 67, 440-446 (2006).
28. Martinon, F., Burns, K. & Tschopp, J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10, 417-426 (2002).
29. Martinon, F., Mayor, A. & Tschopp, J. The inflammasomes: guardians of the body. Annu Rev Immunol 27, 229-265 (2009).
30. Kumar, A. et al. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 183, 949-958 (1996).
31. Toldo, S. et al. Interleukin-18 mediates interleukin-1-induced cardiac dysfunction. Am J Physiol Heart Circ Physiol 306, H1025-1031 (2014).
32. Toldo, S. et al. Recombinant human interleukin-1 receptor antagonist provides cardioprotection during myocardial ischemia reperfusion in the mouse. Cardiovasc Drugs Ther 26, 273-276 (2012).
33. Van Tassell, B. W., Seropian, I. M., Toldo, S., Mezzaroma, E. & Abbate, A. Interleukin-1beta induces a reversible cardiomyopathy in the mouse. Inflamm Res 62, 637-640 (2013).
34. Zhang, Y. & Kompa, A. R. A practical guide to subtotal nephrectomy in the rat with subsequent methodology for assessing renal and cardiac function. Nephrology (Carlton) 19, 552-561 (2014).
35. Connelly, K. A. et al. Load-sensitive measures may overestimate global systolic function in the presence of left ventricular hypertrophy: a comparison with load-insensitive measures. Am J Physiol Heart Circ Physiol 290, H1699-1705 (2006).
36. Georgakopoulos, D. et al. In vivo murine left ventricular pressure-volume relations by miniaturized conductance micromanometry. Am J Physiol 274, H1416-1422 (1998).
37. Lehr, H. A., van der Loos, C. M., Teeling, P. & Gown, A. M. Complete chromogen separation and analysis in double immunohistochemical stains using Photoshop-based image analysis. J Histochem Cytochem 47, 119-126 (1999).
38. Kai, H. et al. Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circ Res 83, 594-601 (1998).
39. Connelly, K. A. et al. Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. Cardiovasc Res 76, 280-291 (2007).
40. Wu, L. L. et al. Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: role of the reninangiotensin system. Kidney Int 51, 1553-1567 (1997).